Study of Ruxolitinib in Colorectal Cancer Patients

Stopped Substudy 1 was terminated for futility at interim analysis and Substudy 2 was terminated per sponsor decision.

Conditions

• CRC (Colorectal Cancer)

Interventions

• DRUG: Ruxolitinib
• DRUG: Regorafenib
• DRUG: Placebo

Sponsor

Incyte Corporation